These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 21839402

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States.
    Villacorta R, Hay JW, Messali A.
    Pharmacoeconomics; 2013 Sep; 31(9):823-39. PubMed ID: 23975739
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis.
    Ferrándiz C, García A, Blasco AJ, Lázaro P.
    J Eur Acad Dermatol Venereol; 2012 Jun; 26(6):768-77. PubMed ID: 22126264
    [Abstract] [Full Text] [Related]

  • 6. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R.
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.
    Uhlenhake EE, Feldman SR.
    Expert Opin Biol Ther; 2010 Jul; 10(7):1105-12. PubMed ID: 20446825
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Infliximab for the treatment of adults with psoriasis.
    Loveman E, Turner D, Hartwell D, Cooper K, Clegg A.
    Health Technol Assess; 2009 Jun; 13 Suppl 1():55-60. PubMed ID: 19567215
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness analysis of TNF-alpha blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system.
    de Portu S, Del Giglio M, Altomare G, Arcangeli F, Berardesca E, Calzavara-Pinton P, Lotti T, Martini P, Peserico A, Simonacci M, Vena GA, Girolomoni G.
    Dermatol Ther; 2010 Jun; 23 Suppl 1():S7-13. PubMed ID: 20136921
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients.
    Young MS, Horn EJ, Cather JC.
    Expert Rev Clin Immunol; 2011 Jan; 7(1):9-13. PubMed ID: 21162644
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.